Have a personal or library account? Click to login
Prevalence and Correlates of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes in Uganda: A Hospital-Based Cross-sectional Study Cover

Prevalence and Correlates of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes in Uganda: A Hospital-Based Cross-sectional Study

Open Access
|Mar 2020

Figures & Tables

Table 1

Algorithm for classification of CAN (CAN score).

TestsPoint 0Point 0.5Point 1
Resting heart rate<100 beats/min100–110 beats/min>110 beats/min
Postural hypotension (fall in systolic blood pressure)<20 mmHg20–30 mmHg>30 mmHg
Valsalva ratio>1.21.2–1.10<1.10
Heart rate variability on deep breathing>15 beats/min15–10 beats/min<10 beats/min
Increase in diastolic blood pressure during sustained handgrip>15 mmHg15–10 mmHg<10 mmHg

[i] CAN: Cardiovascular autonomic neuropathy.

gh-15-1-765-g1.png
Figure 1

Study profile.

Table 2

Baseline demographic and clinical characteristics by CAN status.

CharacteristicTotal cohort (N = 299)Positive for CAN (N = 156)No evidence of CAN (N = 143)P value
Age, in years, mean (SD)50.1 (±9.8)52.8 (±8.7)47.2 (±10.2)<0.001
Female sex (%)208 (69.6)122 (78.2)86 (60.1)0.001
Ever attended school, yes (%)233 (77.9)115 (73.7)118 (82.5)0.067
Occupation
    Peasant (%)175 (58.5)103 (66.0)72 (50.4)0.006
    Student (%)6 (2.0)2 (1.3)4 (2.8)0.351
    Businessman (woman) (%)64 (21.4)29 (18.6)35 (24.5)0.215
    Civil servant (%)51 (17.1)26 (16.7)25 (17.5)0.851
Ever smoked, yes (%)70 (23.4)37 (23.7)32 (22.4)0.783
Currently smoking, yes (%)18 (25.7)11 (29.0)7 (21.9)0.500
Duration of diabetes in years, mean (SD)5.8 (±5.9)7.5 (±6.9)3.9 (±3.9)<0.001
BMI (kg/m2), mean (SD)27.4 (±5.6)27.5 (±5.9)27.3 (±5.2)0.685
Waist circumference in cm, mean (SD)98.2 (±13.6)99.9 (±14.3)96.4 (±12.7)0.025
History of vigorous physical activity (≥600 METS/Week) (%)173 (57.9)89 (57.1)84 (58.7)0.087
Fasting blood sugar in mmol/L, mean (SD)11.2 (±4.8)11.8 (±5.2)10.5 (±4.3)0.021
HbA1c (%), mean(SD)9.7 (±6.7)9.7 (±2.5)9.6 (± 2.7)0.506
Resting heart rate in beats/min, mean (SD)76.6 (±13.1)79.2 (±14.7)73.6 (±10.4)<0.001
Systolic blood pressure in mmHg, mean (SD)141.7 (±22.6)148.6 (±23.2)134.2 (±19.4)<0.001
Diastolic blood pressure in mmHg, mean (SD)87.1 (±10.7)88.8 (±10.7)85.4 (±10.5)0.006
Pulse pressure in mmHg, mean (SD)54.6 (±17.8)59.9 (±19.4)48.8 (±13.8)<0.001
Mean arterial pressure (mmHg)105.3 (±13.3)108.7 (±13.1)101.6 (±12.5)<0.001
Retinopathy<0.001
    None (%)231 (77.3)106 (68.0)125 (87.4)
    Non-proliferative (%)53 (17.7)35 (22.4)18 (12.6)
    Proliferative (%)15 (5.0)15 (9.6)0 (0.0)
History of neuropathy symptoms in past 6 months
    Palpitations, yes (%)149 (49.8)93 (59.6)56 (39.2)<0.001
    Fainting or blackouts, yes (%)114 (38.1)63 (40.4)51 (35.7)0.401
    ‘Dead feeling’, pricking or burning sensation in the feet, yes (%)183 (61.2)105 (67.3)78 (54.6)0.024
QTc interval (ms), mean (SD)428.4 (±22.3)438.4 (±22.0)417.5 (±16.8)<0.001

[i] SD: Standard deviation; CAN: Cardiovascular Autonomic Neuropathy; MET: Metabolic Equivalent Task.

Table 3

Prevalence of CAN by the different assessment methods.

N = 299
Resting tachycardia (pulse rate ≥100 bpm)175.7
Abnormal postural index (≤1.0)4013.4
HRV: Reduced E/I ratio with deep breathing (<15 bpm),12541.8
Valsalva ratio: (<1.2), (N = 284)*5218.3
Postural hypotension5217.4
Diastolic BP response to sustained hand grip (<15 mmHg)10836.1

[i] HRV: Heart rate variability; E/I: Expiration to inspiration ratio.

* Sample size is less by 15 participants who had proliferative retinopathy and were excluded from the valsalva maneuver.

Table 4

Prevalence of CAN by severity (Classification of CAN).

N = 299
Absent14347.8
Early8829.4
Definite/Confirmed6120.4
Severe/Advanced72.3
TOTAL299100.0
gh-15-1-765-g2.png
Figure 2

Graph showing variation of prevalence of CAN by severity with age.

Table 5

Demographic and clinical factors correlated with CAN.

% CAN positiveUnivariable AnalysisMultivariable Analysisp value
Characteristicn/N (%)OR 95%CIp valueaOR 95%CI
Age category(years)
    <357/29 (24.1)RefRef
    35–5039/86 (45.4)2.61 (1.01–6.75)0.0482.10 (0.77-5.74)0.147
    51–65110/184 (59.8)4.67 (1.90–11.49)0.0013.48 (1.35–8.99)0.010
Sex
    Male34/91 (37.4)RefRef
    Female122/208 (58.7)2.38 (1.43–3.95)0.0011.85 (0.94-3.66)0.076
Duration of diabetes in years
    <5years74/170 (43.5)RefRef
    5–9 years38/76 (50.0)1.30 (0.75–2.23)0.3471.04 (0.58–1.88)0.893
    10 years and above44/53 (83.0)6.34 (2.91–13.81)<0.0014.09 (1.78–9.38)0.001
Fasting blood sugar category
    ≤7.0 mmol/L24/60 (40.0)RefRef
    >7.0 mmol/L132/239 (55.2)1.85 (1.04–3.29)0.0361.62 (0.86–3.04)0.135
Blood pressure category
    ≤130/80 mmHg18/60 (30.0)Ref
    >130/80 mmHg105/168 (62.5)3.89 (2.06–7.33)<0.001
Waist circumference
    Normal fat distribution26/62 (41.9)RefRef
    Moderate central fat distribution19/48 (39.6)0.91 (0.42–1.95)0.8040.66 (0.28–1.55)0.339
    High central fat accumulation111/189 (58.7)1.97 (1.10–3.53)0.0221.16 (0.53–2.52)0.709
Retinopathy
    Absent106/231 (45.9)RefRef
    Present50/68 (73.5)3.28 (1.80–5.95)<0.0012.25 (1.16–4.34)0.016
History of Palpitations in past 6 months
    No63/150 (42.0)Ref
    Yes93/149 (62.4)2.29 (1.44–3.65)<0.001
Symptoms of distal peripheral neuropathy
    No51/116 (44.0)Ref
    Yes105/183 (57.4)1.72 (1.07–2.74)0.024
Resting heart rate
    ≤85 beats/min102/227(44.9)Ref
    >85 beats/min54/72 (75.0)3.68 (2.03–6.66)<0.001
QTc interval
    ≤440 ms74/213 (34.7)Ref
    >440 ms82/86 (95.4)38.51 (13.58–109.21)<0.001

[i] aOR: Adjusted Odds Ratio; Ref: Reference Category; CI: Confidence interval; QTc: Heart rate corrected QT.

DOI: https://doi.org/10.5334/gh.765 | Journal eISSN: 2211-8179
Language: English
Submitted on: Oct 5, 2019
|
Accepted on: Jan 28, 2020
|
Published on: Mar 2, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2020 Richard Migisha, David Collins Agaba, Godfrey Katamba, Teddy Kwaga, Raymond Tumwesigye, Silvia Lopez Miranda, Anthony Muyingo, Mark J. Siedner, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.